Monthly Archives: January 2023

US FDA approves Lecanemab for the treatment of Alzheimer’s disease.

    Btobioinnovation.com  Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com     SPECIAL REPORT #23.2   US FDA approves Lecanemab for the treatment of Alzheimer’s disease.     On January 6, the US FDA approved Eisai’s lecanemab, a beta amyloid antibody, via the Accelerated Approval pathway, for use in patients with mild cognitive impairment from […]

read more